Rezolute, Inc.

Happy New Year from #Rezolute! 🎆 Here's a look at some of our 2024 milestones. We will continue to transform care for patients with rare diseases. Thank you for being a part of our journey! #Rezolute #Healthcare #HappyNewYear2025

We are thrilled to announce ersodetug has received Orphan Drug Designation for the treatment of hypoglycemia due to tumor hyperinsulinism (HI). This important recognition allows us to continue developing a potential universal treatment for hypoglycemia caused by all forms of HI. Read more: https://bit.ly/4il4xJW

November is National Family Caregivers Month. We are caregivers, loved ones, and patients on a mission to develop therapies that make a difference. This month we also had the honor of attending the Congenital Hyperinsulinism International Family Conference in Liverpool and are grateful to have a community of patients, families, physicians, and researchers working to improve the lives of those living with HI. The role of caregiver can be filled with challenges and complexities, but also comes with many rewards and a profound impact on families and communities. Thank you to all caregivers for your hard work and commitment! #Caregiver #ResourcesForCaregivers #FamilyCaregiversMonth

What is Tumor Hyperinsulinism (HI)? 🤔 Tumor HI is a rare disease in which a tumor overproduces insulin or insulin-like substances causing severe hypoglycemia, which can be life-threatening. Years of misdiagnosis and poor management have left patients to deal with the consequences of hypoglycemia, which can include seizures and brain damage, and the inability to receive tumor-directed therapies. Here's how RZ358 (ersodetug) can help 🦸♂️ An antibody designed to treat all forms of HI that has received FDA clearance for a Phase 3 registrational study in tumor HI patients based on real-world benefit already demonstrated in patients on a compassionate use basis. Learn more about the promising findings in The New England Journal of Medicine: https://bit.ly/3YKgpvP #hyperinsulinism #hypoglycemia #raredisease #cancer

We're #hiring! Learn more about Rezolute and check out new opportunities to join our rapidly growing team: https://lnkd.in/ecAZetUr

Today is World Neuroendocrine Cancer Day. Together, we can help support individuals impacted by neuroendocrine tumors (NETs), a group of rare cancers that develop in hormone-producing cells across the body, including the pancreas, and are frequently misdiagnosed. NETs, like many other tumors, can overproduce insulin or insulin-like substances, leading to tumor hyperinsulinism (HI) and severe hypoglycemia. If left untreated, tumor HI can significantly impact quality of life and the ability to receive tumor-directed therapies. Learn the signs and symptoms of NETs to encourage earlier diagnosis and awareness: https://lnkd.in/gYuPmfcZ Together, we can make a difference! 🦓 #NETCancerDay #RareDisease #CancerAwareness #letstalkaboutnets #cancer

We look forward to participating in the upcoming Guggenheim Securities and Jefferies healthcare conferences taking place this month. Make sure to contact your respective representatives to meet with the Rezolute management team! https://bit.ly/3NXGmTN

The Rezolute team had a great time at the 15th Annual German Family Conference hosted by Kongenitaler Hyperinsulinismus, eV last week in Berlin! We are grateful to the organizers for giving us the opportunity to meet with families, hear their stories, and share our novel approach to a potential treatment for #cHI.  #sunRIZE #hyperinsulinism #hypoglycemia #raredisease

As #HypoglycemiaAwarenessWeek comes to a close, Rezolute would like to shine a spotlight on the outstanding work our partner patient advocacies do each and every day to support patients and families living with #CongenitalHyperinsulinism. congenitalhi.org hyperinsulinism.co.uk https://lnkd.in/e3Ev92za hyperinsulinismus.de #hypoglycemia #clinicaltrials #raredisease

Compassionate use programs play a crucial, yet often underappreciated, role in drug development; providing patients, particularly those with rare diseases, access to potentially life-saving therapies that may positively impact the trajectory of their health outcomes.   We're thrilled to publish, in partnership with WEP Clinical and Ana Paula Tediosi, this two-part series on compassionate use programs and the meaningful benefits in the development of a potential treatment for multiple forms of insulin receptor mediated hypoglycemia. https://bit.ly/4eXiL0O #clinicaltrials #clinicalresearch #raredisease #hypoglycemiaawarenessweek